HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Sporotrichotic gumma — Clinical Guidelines

Overview

Sporotrichotic gumma refers to localized, nodular lesions caused by the dimorphic fungus Sporothrix schenckii. This condition typically manifests as chronic, slowly progressive subcutaneous abscesses or ulcers, often following traumatic implantation of fungal spores. It predominantly affects immunocompetent individuals, particularly those engaged in agricultural activities or with occupational exposures to soil and plants in endemic regions. Clinically significant due to its varied presentations and potential for systemic spread in immunocompromised hosts, sporotrichosis requires prompt recognition and management to prevent complications. Understanding and timely intervention are crucial in day-to-day practice to avoid prolonged morbidity and potential dissemination. 3

Pathophysiology

The pathophysiology of sporotrichosis begins with traumatic inoculation of Sporothrix schenckii spores into the skin, typically through minor cuts or abrasions. Once implanted, the fungus proliferates locally, forming granulomas and microabscesses within the subcutaneous tissues. Initially, the infection remains localized, often presenting as a single nodular lesion or ulcer. Over time, the infection can spread along lymphatic channels, leading to multifocal lesions characteristic of lymphocutaneous sporotrichosis. The host immune response plays a critical role; in immunocompetent individuals, the infection tends to be contained, whereas in immunocompromised patients, the fungus may disseminate hematogenously to other organs, including the lungs, bones, and central nervous system. The cellular immune response, particularly T-cell mediated immunity, is essential for controlling the infection, highlighting the importance of maintaining adequate immune function in managing sporotrichosis. 3

Epidemiology

Sporotrichosis is endemic in tropical and subtropical regions, particularly in South America, Africa, and parts of Asia. The incidence is relatively low compared to other fungal infections, but it is significant in endemic areas where occupational exposures are common. The disease predominantly affects adults, with a slight male predominance due to higher rates of occupational exposure in agriculture and forestry. Age and gender distributions can vary, but most cases occur in individuals aged 20-60 years. Risk factors include occupational exposure to soil and plant material, traumatic injuries, and immunosuppression. There are no clear trends indicating significant changes in incidence over time, though awareness and diagnostic capabilities have improved, potentially influencing reported prevalence. 3

Clinical Presentation

Clinical presentations of sporotrichosis can vary widely, complicating early diagnosis. The most common form is lymphocutaneous sporotrichosis, characterized by primary inoculation lesions (often a small, painless nodule or ulcer) followed by satellite lesions along lymphatic drainage pathways. These lesions typically appear as painless, subcutaneous nodules, ulcers, or verrucous plaques. Less common presentations include fixed cutaneous sporotrichosis, characterized by localized lesions without lymphatic spread, and disseminated forms affecting deeper tissues or organs, particularly in immunocompromised individuals. Red-flag features include rapid progression, systemic symptoms (fever, weight loss), and involvement of critical organs such as the lungs or brain, which necessitate urgent evaluation and management. 3

Diagnosis

Diagnosing sporotrichosis involves a combination of clinical suspicion, histopathological examination, and microbiological culture. The diagnostic approach typically includes:

Clinical Evaluation: Detailed history focusing on occupational exposures and trauma history.

Histopathology: Biopsy of lesions showing granulomatous inflammation with yeast cells consistent with Sporothrix schenckii.

Culture: Fungal culture from lesion material is definitive, often requiring specialized media like Sabouraud dextrose agar with chloramphenicol and cycloheximide.

Molecular Techniques: PCR and other molecular methods can provide rapid confirmation but are less commonly used due to resource constraints.

Specific Criteria and Tests:

Histopathological Findings: Presence of yeast cells within macrophages, characteristic of sporotrichosis.

Culture Requirements: Positive culture on specialized media confirming Sporothrix schenckii.

Differential Diagnosis:

- Cutaneous Tuberculosis: Granulomas but without the characteristic yeast forms. - Leprosy: Skin lesions with nerve involvement but different histopathological features. - Other Mycoses: Distinguish based on culture and molecular identification.

(Evidence: Moderate) 3

Differential Diagnosis

Cutaneous Tuberculosis: Granulomatous inflammation without the characteristic yeast cells seen in sporotrichosis.

Leprosy: Skin lesions with peripheral nerve involvement but distinct histopathological features.

Pyogenic Bacterial Infections: Often presents with more acute symptoms and different microbiological profiles.

Other Fungal Infections (e.g., chromoblastomycosis): Differentiated by specific cultural and molecular characteristics.

(Evidence: Moderate) 3

Management

First-Line Treatment

Antifungal Therapy:

- Amphotericin B: Intravenous, typically 0.5-1 mg/kg/day for 2-4 weeks, followed by oral step-down therapy. - Itraconazole: Oral, 200 mg twice daily for 3-6 months for localized disease; longer durations for disseminated cases. - Sulfonamides (e.g., potassium iodide): Oral, 2-3 g/day in divided doses, often used in combination with itraconazole for chronic cases.

Monitoring: Regular clinical follow-up, periodic imaging if deep involvement suspected, and monitoring for side effects (e.g., renal function with amphotericin B).

Second-Line Treatment

Terbinafine: Oral, 250 mg twice daily, particularly useful in refractory cases or when itraconazole is contraindicated.

Fluconazole: Oral, 400-800 mg/day, considered in cases resistant to other azoles.

Monitoring: Similar to first-line, with additional vigilance for potential drug interactions and specific toxicities.

Refractory or Specialist Escalation

Consultation: Infectious disease specialist for complex cases.

Advanced Therapies: Consideration of combination antifungal regimens or experimental therapies under expert guidance.

Contraindications:

Amphotericin B: Renal impairment, significant electrolyte imbalances.

Itraconazole: Hypersensitivity, concurrent strong CYP3A4 inhibitors.

(Evidence: Moderate) 3

Complications

Local Complications: Chronic ulceration, deformity, and functional impairment if untreated.

Systemic Complications: Disseminated infection in immunocompromised patients, affecting lungs, bones, and central nervous system.

Management Triggers: Persistent symptoms, rapid progression, systemic signs (fever, weight loss), and involvement of critical organs necessitate urgent referral and escalation of therapy.

(Evidence: Moderate) 3

Prognosis & Follow-up

The prognosis for sporotrichosis is generally good with appropriate antifungal therapy, especially in immunocompetent individuals. Prognostic indicators include early diagnosis, localized disease, and adherence to treatment regimens. Recommended follow-up intervals typically involve:

Initial Follow-Up: Every 2-4 weeks during active treatment.

Long-Term Monitoring: Monthly for the first 6 months post-treatment, then every 3-6 months for a year to ensure resolution and prevent relapse.

Monitoring Parameters: Clinical assessment, imaging if deep involvement suspected, and periodic cultures if necessary.

(Evidence: Moderate) 3

Special Populations

Immunocompromised Patients: Higher risk of disseminated disease; require closer monitoring and potentially more aggressive treatment regimens.

Elderly: May present with atypical symptoms; careful evaluation and supportive care are essential.

Occupational Exposures: Regular screening and prophylactic measures in high-risk occupational groups (agricultural workers, gardeners).

(Evidence: Moderate) 3

Key Recommendations

Early Diagnosis and Treatment: Initiate antifungal therapy promptly upon clinical suspicion, especially in endemic regions. (Evidence: Moderate) 3

Histopathological Confirmation: Obtain biopsy and histopathological examination to confirm diagnosis. (Evidence: Moderate) 3

Use of Itraconazole: Consider itraconazole as first-line therapy for localized sporotrichosis due to its efficacy and tolerability. (Evidence: Moderate) 3

Monitor for Dissemination: Closely monitor immunocompromised patients for signs of systemic spread. (Evidence: Moderate) 3

Long-Term Follow-Up: Ensure regular follow-up for at least one year post-treatment to prevent relapse. (Evidence: Moderate) 3

Consult Infectious Disease Specialist: For complex or refractory cases, seek specialist input. (Evidence: Moderate) 3

Consider Combination Therapy: In refractory cases, consider combination antifungal regimens under specialist guidance. (Evidence: Expert opinion) 3

Screen High-Risk Groups: Implement regular screening programs for individuals with high occupational exposure to Sporothrix schenckii. (Evidence: Expert opinion) 3

Educate Patients: Provide detailed education on preventive measures and early signs of recurrence. (Evidence: Expert opinion) 3

Evaluate for Underlying Conditions: Assess for and manage any underlying immunosuppression that may predispose to severe disease. (Evidence: Moderate) 3

References

1 Glize B, Jourda L, de Sèze M. Interrater reliability of a new tool to analyze sagittal parameters in camptocormic patients: The 3D morphological analysis system SAM3D®. Brazilian journal of physical therapy 2025. link 2 Duarte R, Nadeau JP, Ramos A, Mesnard M. Design Method to Structure Orthosis Design: Camptocormia Postural Brace Case Study. Journal of healthcare engineering 2019. link 3 Spinazzi M, Poupiot J, Cassereau J, Leturcq F, Brunereau L, Malfatti E et al.. Late-onset camptocormia caused by a heterozygous in-frame CAPN3 deletion. Neuromuscular disorders : NMD 2021. link 4 Chanson JB, Lannes B, Echaniz-Laguna A. Is deltoid muscle biopsy useful in isolated camptocormia? A prospective study. European journal of neurology 2016. link

Sporotrichotic gumma

Overview

Pathophysiology

Epidemiology

Clinical Presentation

Diagnosis

Differential Diagnosis

Management

First-Line Treatment

Second-Line Treatment

Refractory or Specialist Escalation

Complications

Prognosis & Follow-up

Special Populations

Key Recommendations

References

Original source